Ensysce Biosciences (ENSC) Financials

Ensysce Biosciences (NASDAQ:ENSC) continues to operate as a pre-revenue biotechnology company with substantial cash burn and recurring net losses. The latest quarter showed some sequential improvement in expenses and operating losses, but the company remains dependent on external financing and has a balance sheet with negative equity.

• Sequential loss improvement: Q2 2026 net loss attributable to common shareholders was $2.57 million, compared with $3.56 million in Q1 2026 and $2.77 million in Q4 2025.
• Lower operating expenses: Marketing expense declined to $2.47 million in Q2 2026 from $3.35 million in Q1 and $3.61 million in Q4 2025. Total non-interest expense also fell to $2.58 million from $3.56 million in Q1.
• Financing offset most of the quarterly cash burn: Ensysce generated $1.89 million from financing activities in Q2 2026, reducing the net quarterly cash decrease to only $68,778 despite $1.96 million of operating cash outflow.
• Operating cash flow improved sequentially: Cash used in operations declined from $3.50 million in Q1 2026 to $1.96 million in Q2. This was also better than the $2.71 million outflow in Q2 2025.
• Cash remains limited: Cash and equivalents totaled $676,704 at June 30, 2026, down from $745,482 at March 31 and sharply below $4.15 million at September 30, 2024. The Q2 cash balance covers only a fraction of recent quarterly operating expenses.
• Potentially favorable noncash adjustments: Q2 included $648,180 of noncash adjustments, which helped narrow the difference between the reported net loss and operating cash burn. Investors should not treat these adjustments as recurring operating income.
• No revenue generation: Total revenue has been reported at zero in each provided 2024–2026 quarter. As a result, Ensysce has no operating revenue base to fund research, development, or corporate expenses.
• Persistent cash burn and losses: Operating cash flow has remained negative throughout the reported period, including $1.71 million used in Q1 2025, $1.87 million in Q3 2025, $1.53 million in Q4 2025, $3.50 million in Q1 2026, and $1.96 million in Q2 2026.
• Negative shareholders’ equity: Total liabilities of $4.07 million exceeded total assets of $2.96 million at June 30, 2026, resulting in total equity and noncontrolling interests of negative $1.11 million. This compares with negative $669,012 in Q1 2026 and positive equity in 2025.
• Financing and dilution risk remain high: The company has relied heavily on financing to fund operations, while weighted-average basic shares increased to 13.0 million in Q2 2026 from 6.8 million in Q1 2026 and 2.6 million in Q4 2025. Additional capital raises could further dilute existing shareholders.

The balance sheet has deteriorated materially over the longer period covered by the data. Total assets declined from $9.38 million in Q3 2024 to $2.96 million in Q2 2026, while total liabilities increased from $2.80 million to $4.07 million. Short-term debt and accrued interest payable together totaled approximately $4.07 million in the latest quarter, leaving little balance-sheet cushion.

Q2 2026 provided modest operational improvement, particularly through lower marketing costs and reduced cash burn. However, the improvement was not sufficient to establish a sustainable trend. With zero revenue, recurring losses, negative equity and a cash balance well below quarterly operating requirements, Ensysce will likely need additional financing unless expenses fall substantially or its drug-development programs begin generating meaningful funding or commercial revenue.